Jonsson G, Gorio A, Hallman H, Janigro D, Kojima H, Zanoni R
Brain Res. 1984 Nov;318(2):171-80. doi: 10.1016/0165-3806(84)90023-3.
The effect of exogenous GM1 ganglioside on the 5,7-dihydroxytryptamine (5,7-HT; a selective serotonin neurotoxin) induced alteration of the postnatal development of central 5-hydroxytryptamine (5-HT; serotonin) neurons has been investigated using neuro-chemical and immunocytochemical techniques. Neonatal 5,7-HT (50 mg/kg s.c.) treatment is known to lead to a marked and a permanent degeneration of distant 5-HT nerve terminal projections (e.g. in cerebral cortex, hippocampus and spinal cord), while projections close to the 5-HT perikarya in the mesencephalon and pons-medulla increase their nerve density. These regional alterations are reflected by decreases and increases, respectively, of endogenous 5-HT, [3H]5-HT uptake in vitro and number of 5-HT nerve terminals demonstrated by immunocytochemistry. Treatment of newborn rats with GM1 (4 X 30 mg/kg s.c.; 24 h interval) had no significant effect on the postnatal development of 5-HT neurons. GM1 administration had furthermore no effect on the 5,7-HT induced alteration of the regional 5-HT levels and [3H]5-HT uptake in the cerebral cortex acutely, indicating that GM1 did not significantly interfere with the primary neurodegenerative actions of 5,7-HT. At the age of 1 month a clear counteracting effect of GM1 was observed, in particular of the 5,7-HT induced 5-HT denervations. The 5-HT levels in the frontal and occipital cortex were reduced to 25 and 20% of control after 5,7-HT alone, while these values were 70 and 40%, respectively, after 5,7-HT and GM1 treatment. A similar antagonizing effect of GM1 was found in the frontal cortex when measuring [3H]5-HT uptake. GM1 treatment also caused a minor reduction of the 5,7-HT induced increase of the 5-HT levels in striatum and mesencephalon. Quantitation of 5-HT nerve terminal density in sections processed for 5-HT immunocytochemistry using an automatic image analysis system showed markedly more nerve terminals in the frontal and occipital cortex after 5,7-HT + GM1 compared to 5,7-HT treatment alone. Minor counteracting effects of GM1 were noted in the hippocampus and spinal cord (thoracic-lumbar) as evaluated by chemical 5-HT assay, although substantial counteracting effects were observed locally in these areas by quantitative immunocytochemistry.(ABSTRACT TRUNCATED AT 400 WORDS)
已使用神经化学和免疫细胞化学技术研究了外源性神经节苷脂GM1对5,7 - 二羟基色胺(5,7 - HT;一种选择性5 - 羟色胺神经毒素)诱导的中枢5 - 羟色胺(5 - HT;5 - 羟色胺)神经元出生后发育改变的影响。已知新生大鼠皮下注射5,7 - HT(50 mg/kg)会导致远处5 - HT神经终末投射(如大脑皮层、海马体和脊髓中的投射)显著且永久性退化,而中脑和脑桥 - 延髓中靠近5 - HT神经元胞体的投射神经密度增加。这些区域变化分别通过内源性5 - HT减少、体外[³H]5 - HT摄取减少以及免疫细胞化学显示的5 - HT神经终末数量减少和增加来反映。用GM1(4×30 mg/kg皮下注射;间隔24小时)处理新生大鼠对5 - HT神经元的出生后发育无显著影响。GM1给药对5,7 - HT急性诱导的大脑皮层区域5 - HT水平和[³H]5 - HT摄取的改变也无影响,表明GM1不会显著干扰5,7 - HT的原发性神经退行性作用。在1月龄时观察到GM1有明显的对抗作用,特别是对5,7 - HT诱导的5 - HT去神经支配。单独注射5,7 - HT后额叶和枕叶皮层的5 - HT水平分别降至对照的25%和20%,而在5,7 - HT和GM1联合处理后,这些值分别为70%和40%。在测量额叶皮层的[³H]5 - HT摄取时也发现了GM1类似的拮抗作用。GM1处理还使5,7 - HT诱导的纹状体和中脑5 - HT水平升高略有降低。使用自动图像分析系统对经5 - HT免疫细胞化学处理的切片中的5 - HT神经终末密度进行定量分析显示,与单独5,7 - HT处理相比,5,7 - HT + GM1处理后额叶和枕叶皮层中的神经终末明显更多。通过化学5 - HT测定评估,在海马体和脊髓(胸腰段)中观察到GM1有轻微的对抗作用,尽管通过定量免疫细胞化学在这些区域局部观察到显著的对抗作用。(摘要截断于400字)